ICD-10-CM Billable Code

M11.15

Familial chondrocalcinosis, hip

Clinical Classification Guidelines

Medical Intelligence & Overview

Familial chondrocalcinosis, specifically affecting the hip, is a hereditary condition characterized by the abnormal deposit of calcium within the cartilage of the joint. This condition is part of a broader group known as calcium pyrophosphate dihydrate (CPPD) crystal deposition disease. The presence of calcium deposits leads to joint pain, swelling, and can cause degenerative changes over time. Understanding the origins, symptoms, and management options for this condition can help patients and caregivers navigate the challenges associated with it.

Causes & Symptoms

Clinical Causes: Genetic mutations inherited from family members Predisposition to abnormal calcium metabolism within joint cartilage Age-related changes that enhance crystal formation in susceptible individuals Other metabolic disorders that increase calcium or pyrophosphate levels Environmental factors that may influence disease progression

Key Symptoms: Pain in the hip joint, especially during movement or weight bearing Swelling and tenderness around the affected joint Reduced range of motion in the hip Sensation of joint grinding or catching during movement Potential symptoms of inflammation, such as warmth or redness Possible development of osteoarthritis over time due to cartilage degeneration

Diagnostic & Treatment

Diagnosis Path: The diagnosis of familial chondrocalcinosis of the hip involves a combination of clinical evaluation and diagnostic tests. Key steps include: - **Medical History and Physical Examination:** Assessing family history, symptom patterns, and joint function. - **Imaging Studies:** X-rays are commonly used to detect calcium deposits within the cartilage and assess joint degeneration. Advanced imaging like ultrasound or MRI may provide more detailed visualization. - **Joint Fluid Analysis:** Arthrocentesis (joint aspiration) can help identify calcium pyrophosphate crystals through microscopy, confirming the diagnosis. - **Laboratory Tests:** Blood tests may be performed to evaluate calcium, phosphate, and other metabolic parameters to rule out related conditions. Given its hereditary nature, a detailed family medical history is important for identifying potential genetic predisposition.

Treatment Protocols: While there is no cure for familial chondrocalcinosis, management focuses on alleviating symptoms and minimizing joint damage. Common approaches include: - **Medications:** Nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief and inflammation control; corticosteroid injections in acute flare-ups. - **Physical Therapy:** Exercises to strengthen surrounding muscles and preserve joint function. - **Lifestyle Modifications:** Weight management and activity adjustments to reduce joint stress. - **Monitoring and Follow-up:** Regular assessment to detect progression and manage symptoms proactively. - **Surgical Intervention:** In advanced cases with significant joint damage, procedures such as joint replacement may be considered. Patients are encouraged to work closely with healthcare professionals to develop personalized management plans.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is M11.15 a billable ICD-10 code?
Yes, M11.15 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report M11.15?
Clinical documentation must specify the nature of Familial chondrocalcinosis, hip and any associated comorbidities for accurate reporting.

Cite this Clinical Reference